Dr. Teal’s Tucks In Some Melatonin Topical Sleep Claims After P&G Challenge, Keeps Others Awake
NAD Sends Questions About PDC Brands' Ad Claims To FTC And FDA
PDC Brands declines to provide support for nine challenged claims for Dr. Teal’s line of balms, lotions, oils, soaps, sprays and other topicals. It continues using those after halting use of 25 other similar claims challenged by P&G, marketer of melatonin-containing ZzzQuil.
You may also be interested in...
Companies have one year to comply with US FDA registration and product listing requirements under the Modernization of Cosmetic Regulations Act of 2022, part of the $1.7tr omnibus spending package signed by President Joe Biden on 29 December. Trade groups applauded the historic milestone and the legislation’s departure from previous proposals, including the elimination of user fees.
An ultraviolet lamp marketer was dinged by industry self-regulation for COVID-19 claims; the largest US natural food grocery chain had one too many undeclared allergens for the FDA's liking; and warnings note cannabidiol-containing eye drops, nasal sprays and inhalers promoted with drug claims.
While other national brand names compete in the OTC sleep aid tablet category, P&G’s NyQuil line extension is by far the biggest name among current players in the liquid product category, which has annual growth of nearly 80%.